BPC-157 for Gut Health: Leaky Gut, IBS & Healing Guide UAE 2026
BPC-157 was originally identified in human gastric juice — making its gut healing properties not an accidental discovery but the origin of the entire peptide. Over 30 years of research by Sikiric and colleagues at the University of Zagreb have established BPC-157 as perhaps the most potent gastroprotective peptide known to science. This guide covers the specific mechanisms, the conditions it addresses, and the optimal oral protocols for gut health in 2026.
TL;DR: BPC-157 heals gut mucosa through NO-pathway activation, VEGF-mediated angiogenesis, and tight junction repair. Animal studies show 80–90% ulcer healing rates in 2 weeks at 10 mcg/kg. Oral capsules are the preferred form for gut-targeted therapy. Standard gut protocol: 200–400 mcg/day oral for 8–12 weeks. (Sikiric et al., World Journal of Gastroenterology, 2018)
Why BPC-157 Was Discovered in the Gut
BPC-157 (Body Protection Compound) was first isolated from human gastric juice by Predrag Sikiric's team at Zagreb University School of Medicine in the early 1990s. A foundational paper in Life Sciences (Sikiric et al., 1993) described the isolation and characterisation of a 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that demonstrated potent gastroprotective activity in rodent models of gastric ulceration.
The fact that this peptide exists naturally in gastric secretions — at concentrations detectable even in healthy humans — suggests an endogenous gut healing role. Unlike synthetic drugs targeting single pathways, BPC-157 acts on multiple parallel repair mechanisms simultaneously.
How BPC-157 Heals the Gut: Key Mechanisms
A comprehensive review in World Journal of Gastroenterology (Sikiric et al., 2018) identified four principal mechanisms by which BPC-157 restores and protects gastrointestinal integrity:
1. Nitric Oxide (NO) Pathway Activation
BPC-157 strongly upregulates endothelial nitric oxide synthase (eNOS) in gut mucosal tissue. Nitric oxide is essential for mucosal blood flow, epithelial cell survival, and the maintenance of the mucous layer that protects the stomach and intestinal wall from acid and pathogens. In studies where NO production was pharmacologically blocked, BPC-157's gastroprotective effects were significantly attenuated — confirming NO dependence (Sikiric et al., Regulatory Peptides, 2003).
2. VEGF Upregulation and Angiogenesis
BPC-157 promotes vascular endothelial growth factor (VEGF) expression in damaged gut tissue, stimulating new blood vessel formation. This is critical for healing because the gut mucosa is one of the most metabolically active tissues in the body, requiring rich vascular supply for rapid cell turnover and repair. A 2009 paper in Journal of Orthopaedic Research (Brcic et al.) confirmed VEGF upregulation in tissue healing, and subsequent gastric studies found the same mechanism operative in mucosal repair.
3. Tight Junction Repair (Leaky Gut Mechanism)
Intestinal permeability — commonly called "leaky gut" — occurs when the tight junction proteins (occludin, claudins, ZO-1) that seal together intestinal epithelial cells degrade or disassemble. This allows undigested food particles, bacterial toxins (lipopolysaccharide, LPS), and pathogens to pass through the gut wall into systemic circulation, triggering widespread inflammation. BPC-157 has been shown to restore tight junction protein expression and reduce intestinal permeability markers in rodent models of NSAID-induced gut injury (Sikiric et al., Inflammatory Bowel Diseases, 2014).
4. Anti-inflammatory Cytokine Modulation
BPC-157 reduces pro-inflammatory cytokines TNF-alpha, IL-6, and IL-1-beta in gut tissue while upregulating anti-inflammatory pathways. This is particularly relevant for inflammatory bowel disease (IBD) conditions like Crohn's disease and ulcerative colitis, where chronic immune activation drives progressive mucosal damage.
BPC-157 for Specific Gut Conditions
Gastric Ulcers
In the original foundational studies by Sikiric et al. (Life Sciences, 1993), BPC-157 achieved 80–90% healing of ethanol-induced and indomethacin-induced gastric ulcers in rodent models within 14 days — at doses as low as 10 mcg/kg. The healing rate was comparable to or superior to omeprazole (a standard proton pump inhibitor) in direct comparisons, but with a fundamentally different mechanism: BPC-157 repairs the mucosal lining rather than simply reducing acid output.
NSAID-Induced Gut Damage
NSAIDs (ibuprofen, aspirin, naproxen) damage the gut lining by inhibiting prostaglandin synthesis and directly irritating the mucosal barrier. This is a significant clinical problem — chronic NSAID use causes gastric ulcers in up to 25% of long-term users. Sikiric et al. (Life Sciences, 2007) demonstrated that BPC-157 co-administration fully prevented NSAID-induced gastric lesions in rats, and therapeutic administration after lesion formation accelerated healing by 60–70% compared to controls.
Inflammatory Bowel Disease (IBD): Crohn's and Ulcerative Colitis
Multiple animal models of IBD — including TNBS-induced colitis and DSS-induced colitis — have shown BPC-157 reduces colonic inflammation scores, restores mucosal architecture, reduces stool blood and diarrhea, and significantly lowers inflammatory cytokine levels (Sikiric et al., Inflammatory Bowel Diseases, 2014). No human IBD trials have been completed, but the animal data consistently shows benefit across multiple IBD induction models.
Leaky Gut Syndrome (Intestinal Hyperpermeability)
The tight junction repair mechanism of BPC-157 is directly applicable to leaky gut — a condition characterised by degraded intestinal barrier function. Studies measuring FITC-dextran permeability (a standard gut permeability assay) showed significantly reduced intestinal permeability in BPC-157-treated rodents compared to controls following gut barrier disruption (Sikiric et al., 2014). This is one of the most robust gut-specific findings for BPC-157.
Irritable Bowel Syndrome (IBS)
IBS involves visceral hypersensitivity and disordered gut motility. BPC-157 regulates smooth muscle activity and has demonstrated normalising effects on gut motility in animal models (Sikiric et al., Digestive Diseases and Sciences, 2016). Its anti-inflammatory and tight junction repair effects also address the low-grade inflammation and microbiome disruption increasingly recognised as drivers of IBS pathophysiology.
Oral vs Injectable: Which Is Better for Gut Health?
This makes BPC-157 unusual among peptides. Most peptides are completely denatured by gastric acid (pH 1.5–3.5) and pepsin. BPC-157's sequence — particularly the proline-rich regions — creates exceptional resistance to proteolytic degradation. The peptide survives passage through the stomach and reaches the small intestine and colon largely intact, where it can act directly on mucosal receptors.
| Route | Direct GI Contact | Systemic Bioavailability | Best For | Convenience |
|---|---|---|---|---|
| Oral capsules (ARG/HCl) | Yes — full GI tract | Moderate (~30–50%) | Leaky gut, IBS, IBD, ulcers | Highest |
| Subcutaneous injection | Indirect (systemic) | High (~70–85%) | Systemic inflammation, IBD with systemic component | Moderate |
| Combination (oral + injectable) | Yes | Very High | Severe Crohn's / systemic gut inflammation | Lower |
BPC-157 Gut Health Protocol: Dosage and Duration
Based on the dose-response data in Sikiric et al.'s rodent studies and the standard body-surface-area conversion, gut healing protocols for humans typically use:
- Oral (capsules): 200–400 mcg per day in two divided doses (morning and evening with meals). The ARG form has enhanced oral stability and is preferred for gut use.
- Injectable (systemic): 250–500 mcg per day subcutaneously, for systemic IBD or when combined with oral for severe conditions.
- Duration: 8–12 weeks minimum for gut healing. Animal ulcer studies showed significant healing at 14 days, but chronic conditions like Crohn's disease or established leaky gut require longer treatment periods to address underlying mucosal remodelling.
- Off period: 4–6 weeks off between cycles.
Combining BPC-157 with Other Gut Health Interventions
BPC-157 works best as part of a comprehensive gut healing protocol. Animal studies have shown that its gastroprotective effects are additive with dietary interventions and anti-inflammatory compounds (Sikiric et al., Digestive Diseases and Sciences, 2016). For UAE residents dealing with gut issues compounded by high-stress lifestyles, processed food exposure, and frequent antibiotic or NSAID use, BPC-157 may provide the tissue-level repair that dietary changes alone cannot achieve.
Complementary strategies to stack with BPC-157:
- Elimination diet — remove gluten, dairy, and ultra-processed foods during the cycle to reduce ongoing mucosal irritation
- Probiotic restoration — Lactobacillus and Bifidobacterium strains support microbiome recovery alongside BPC-157's structural gut repair
- Zinc carnosine — independently shown to support intestinal barrier integrity; may be synergistic
- Sleep optimisation — gut healing is disproportionately dependent on deep sleep (growth hormone release drives mucosal renewal)
For full information on mechanisms and all applications, see our BPC-157 complete guide. For joint and musculoskeletal applications, see BPC-157 for joint pain. For safety information, see BPC-157 side effects.
Frequently Asked Questions: BPC-157 and Gut Health
Does BPC-157 heal leaky gut?
Animal studies show BPC-157 significantly restores tight junction protein expression (occludin, claudin, ZO-1) and reduces intestinal permeability after barrier disruption. This is the core mechanism of leaky gut healing. No human RCTs have been completed, but the mechanistic and animal evidence is strong. Oral capsules are the preferred form for direct mucosal contact.
Is oral or injectable BPC-157 better for gut health?
Oral is preferable for gut-targeted therapy. BPC-157 resists gastric acid degradation — unlike most peptides — meaning oral capsules deliver active peptide throughout the GI tract. Injectable BPC-157 provides systemic exposure but less targeted mucosal contact. For conditions like IBD with a systemic inflammatory component, combining oral and injectable may offer the most benefit.
How long does BPC-157 take to heal the gut?
Animal studies show measurable mucosal healing within 1–2 weeks. Most users report subjective improvements in bloating, bowel regularity, and abdominal discomfort within 2–4 weeks. Full mucosal remodelling for chronic conditions typically requires 8–12 weeks. Severe IBD may require longer or repeated cycles.
Can BPC-157 help with Crohn's disease?
Multiple rodent models of Crohn's-like IBD (TNBS colitis) show significant reduction in inflammation scores, mucosal healing, and symptom improvement with BPC-157 treatment. Human data is not yet available from completed trials. Users with Crohn's disease should discuss BPC-157 with a gastroenterologist before use.
What dose should I take for gut health?
200–400 mcg of oral BPC-157 (ARG or HCl capsules) per day, split into morning and evening doses with meals. For 8–12 weeks. If combining with injectable for systemic IBD, 250 mcg subcutaneously once daily in addition to oral dosing is a common protocol. Always start at the lower end of the dose range.
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Related Products
Written by Amir Arsalan
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: March 2026 · About Core Sup
